Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Innovent Biologics, Inc.

http://www.innoventbio.com/en/

Latest From Innovent Biologics, Inc.

China Approval For Akeso’s Bispecific But ASCO Data Unnerve Investors

Ivonescimab in combination with chemotherapy reduced the risk of disease progression or death by 54% versus placebo in EGFR-mutated, non-squamous NSCLC after failed EGFR inhibitor treatment. However, the progression-free survival data did little to satisfy investors’ demand for clear benefits versus competitors. 

China Approvals

‘Do It Or We’re Not Going To Approve Your Drug:’ Industry Reps Ask FDA For Trial Diversity Sticks

FDA leadership has generally seemed apprehensive of going too hard on companies that don’t meet clinical trial diversity goals, but some industry insiders say a stronger FDA is needed to spark real change. Delayed guidance could indicate if the agency will change course.

Clinical Trials Diversity & Inclusion

Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive

The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.

China Research & Development

China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes

The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.

China United States
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Other Names / Subsidiaries
    • Innovent Biologics (Suzhou) Co., Ltd.
UsernamePublicRestriction

Register